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Background: Wiedemann-Steiner Syndrome (WSS) is characterized by short stature, a variety of dysmorphic facial
and skeletal features, characteristic hypertrichosis cubiti (excessive hair on the elbows), mild-to-moderate
developmental delay and intellectual disability. [MIM#: 605130]. Here we report two unrelated children for whom
clinical exome sequencing of parent-proband trios was performed at UCLA, resulting in a molecular diagnosis of
WSS and atypical clinical presentation.
Case presentation: For patient 1, clinical features at 9 years of age included developmental delay, craniofacial
abnormalities, and multiple minor anomalies. Patient 2 presented at 1 year of age with developmental delay,
microphthalmia, partial 3–4 left hand syndactyly, and craniofacial abnormalities. A de novo missense c.4342T>C
variant and a de novo splice site c.4086+G>A variant were identified in the KMT2A gene in patients 1 and 2,
respectively.
Conclusions: Based on the clinical and molecular findings, both patients appear to have novel presentations of
WSS. As the hallmark hypertrichosis cubiti was not initially appreciated in either case, this syndrome was not
suspected during the clinical evaluation. This report expands the phenotypic spectrum of the clinical phenotypes
and KMT2A variants associated with WSS.
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delayBackground
Patients presenting with developmental delay and multiple
dysmorphic features are a common diagnostic challenge in
the genetics clinic. Over the past decade, many new genetic
syndromes have been identified within this area. A signifi-
cant number of these have been linked to genes involved
in histone modification and chromatin remodeling. These* Correspondence: Fquintero@mednet.ucla.edu
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unless otherwise stated.include: Kabuki syndrome types 1 and 2 [MIM:147920 and
300867] [1,2], Kleefstra syndrome [MIM: 610253] [3],
KAT6B-related disorders [MIM: 606170 and 603736] [4],
Weaver syndrome [MIM: 277590] [5], HDAC8-related dis-
orders [MIM:30882 and 309585] [6-8], and Wiedemann-
Steiner syndrome [MIM: 605130] [9]. These along with
Rubenstein-Taybi [MIM: 180849] [10] and Sotos Syndrome
[MIM 117550] [11] make up a broad range of conditions
cause by defects in chromatin remodeling genes. Similar
to the loss of epigenetic control seen in Rett Syndrome
[MIM: 312750], these disorders are thought to result from
global changes in gene expression throughout develop-
ment leading to abnormalities in multiple body systems.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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paired brain development leading to developmental delay
and/or intellectual disability.
As these chromatin remodeling defect disorders are
rare, with some having only a small number of cases
reported, the complete phenotypic spectrum of many
of them has not been well described. Thus while careful
phenotyping remains critical for clinical diagnosis, it
will often be insufficient to distinguish between related
disorders. Genome-wide clinical tests such as SNP-
based chromosomal microarray testing (SNP-CMA),
clinical exome sequencing (CES), and clinical genome
sequencing are incredibly powerful tools at identifying
disease-causing variants in these genes: SNP CMA de-
tection rate for ID ranges between 10-24% [12], while
the diagnostic yield of exome sequencing, in patients with
normal CMA results, ranges 10-40% [13].
Also of note is the strong pattern of de novo variants
observed in many chromatin remodeling disorders
[1,2,4,9,14]. Complete parent-proband trio sequencing
is warranted in cases with developmental delay and
dysmorphic features, as it has the power to directly
identify de novo variants. In addition to expediting the
process of identifying de novo variants in the known
chromatin remodeling genes, there are many histone
modification genes which have not been associated
with human disease [15]. With complete trio clinical
exome sequencing, it is possible to identify candidate
novel disease gene associations using clinical information
and predictive molecular tools.
The two patients presented in this report were seen at
different medical institutions and by separate medical
teams. Based on the reported clinical findings, there was no
a priori expectation from within the clinical laboratory that
these two individuals were connected in any way. Clinical
exome sequencing was performed on full trios in both cases
using clinically validated protocols (Additional file 1),
detecting unique de novo likely pathogenic variants in
the KMT2A (MLL) gene in each patient.
Fusions between the KMT2A gene with a variety of other
genes are commonly observed in leukemic cells [16,17],
giving the gene its original name: “myeloid/lymphoid or
mixed lineage leukemia gene” or MLL. KMT2A is widely
expressed, detectable in most human tissues [18]. It con-
tains 36 exons and has three known mRNA isoforms
(NM_001197104.1, NM_005933.3, and NM_024891.2). It is
a homologue of the d. melanogaster gene trithorax. Mice
heterozygous for a knockout mutation of the homolo-
gous Ktm2a gene exhibit retarded growth, skeletal and
hematopoietic abnormalities [19,20]. The KMT2A gene
product KMT2A contains several functional domains. One
domain is a SET domain which acts as a histone H3 lysine
4-specific methyltransferase, thus regulating a variety of de-
velopmental genes including those in the HOX family [21].Wiedemann-Steiner Syndrome has been described as a
clinical entity defined by the presence of hypertrichosis
cubiti (hairy elbows) and variable presentation of additional
features such as facial dysmorphism, short stature,
intellectual disability, and developmental delay [22-25].
In an exome sequencing study of WSS, de novo DNA
variants in the KMT2A gene were identified in five out of
six patients, strongly implicating this gene as the major
disease gene for WSS [9].
Case presentation
Patient 1: 9 year-old female of Mexican ancestry
Pre/perinatal history
Prenatal course was normal with vaginal delivery. The
birth weight (3.4 kg, 50–75 centile) and length (49.5 cm,
50-75 centile) were both normal. Head circumference was
not available.
Review of systems
Poor muscle tone was noted at birth, and by 7 months of
age significant general hypotonia and muscle weakness
were apparent. At 20 months her development was signifi-
cantly delayed, both for motor skills (due to continued
hypotonia) and speech production. Poor feeding was noted
at this time. Growth parameters at this age were markedly
low, being below the 3rd centile in height, weight, and head
circumference. Receptive language appeared normal. At
4.5 years of age, premature dental eruption of adult teeth
was noted. Ophthalmic exams were normal except for
correctable astigmatism. Upon intellectual ability testing at
approximately age 5, she had very poor scores for “spatial
ability”, “general conceptual ability” and “special nonverbal
composite”. She scored as average for “nonverbal reasoning
ability” and below average for “verbal ability”. These scores
represent an estimated IQ of approximately 65–75.
Physical exam
At approximately 10 years of age: Height is 165 cm (>95
centile); weight is 50 kg (95 centile).
Dysmorphic features
Hypertelorism, bulbous nose, clinodactyly, downslanting
and short palpebral fissures, a wide and depressed nasal
bridge, thick eyebrows and hair, long thick eyelashes,
synophris, thin lips, hypertelorism (Figure 1A-D, Table 1).
Previous testing
The following tests were all negative/normal: array
comparative genomic hybridization, Fragile X Syndrome
(FMR1 triplet repeat expansion); Rett Syndrome (MECP2
sequencing); Coffin-Lowry Syndrome (RPS6KA3 sequen-
cing); myotonic dystrophy (DMPK sequencing); Prader-
Willi Syndrome (by methylation) 3-hydroxyisobutric aciduria
(valium load testing).
Figure 1 Features of patient 1 (A-D) and patient 2 (E).
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Family history is unremarkable, with one unaffected
sibling who does not share any of the clinical features
noted here. Consanguinity is denied.
Therapy and other interventions
She is enrolled in special education classes and receives
regular speech and occupational therapy. Carnitine supple-
mentation for hypotonia was given with limited response.
She had multiple procedures to remove teeth, and has
suffered multiple urinary tract infections.
Patient 2: 1 year-old male of Caucasian (maternal) and
Mexican (paternal) ancestry
Pre/perinatal history
He was born by Cesarean section at 38 weeks of gestation,
following an uncomplicated pregnancy, to a 21 year oldmother and a 26 year-old father. The birth weight (3.02
kg, 25-50 centile) and head circumference (34.9 cm, 50-75
centile) were both normal, but the birth length of 44.4 cm
was below the fifth centile. Dysmorphic features and
microphthalmia of the right eye were noted at birth. An
ocular prosthetic was placed at ~3 months of age.
Review of systems
He has a history of developmental delay beginning at
4 months of age when failed to achieve milestones (he did
not roll over). At this time, vocalization was normal and
object tracking was mildly impaired. He had a weak grip,
significant central hypotonia, decreased muscle bulk, and
head lagging. At the time of exam (1 year) he uses only
one, non-specific word (‘dada’). He cannot sit up independ-
ently or crawl, but can “scoot”.
Physical exam
Weight 6.24 kg (<3rd centile); length 67 cm (<3rd centile);
head circumference 44.1 cm (5th centile); anterior fontanelle
not fused (1.5 cm × 1.5 cm).
Dysmorphic features
Right microphthalmia, micrognathia, wide nasal bridge,
thick hair, low anterior hairline, two posterior hair whorls,
long and prominent eyelashes, sacral hypertrichosis, small
palpebral fissures which are down-slanted with telecanthus,
tapered fingers, 3–4 partial left-hand syndactyly, mild pectus
excavatum, and small feet and hands (Figure 1E, Table 1).
Previous testing
Normal karyotype (46, XY), SNP-CMA. Normal spinal canal
ultrasound at 4 months of age, ruling out neural tube
defects, and an abdominal ultrasound which ruled out gross
malformations of the liver, gallbladder, pancreas, spleen, and
kidneys. No brain MRI has been performed.
Family history
The family history is unremarkable except for a paternal
half-brother who was born with a unilateral dysplastic
kidney. Two other paternal half-siblings and one full sibling
are healthy, as are the parents. Consanguinity is denied.
Therapy and other interventions
He receives weekly physical and occupational therapies
(started at 5 months). Substantial gains have been made in
the domains of motor functioning and expressive language.
Molecular testing Exome Sequencing was performed in
the UCLA Molecular Diagnostics Laboratories using
clinically validated protocols. The proband and both
parents were sequenced in each case (trio analysis). All
genes harboring de novo, homozygous or compound
heterozygous variants with allele frequencies <1% in the
Table 1 Comparison of clinical features of patients with MLL-related WSS [9] with patient 1 and patient 2
System Phenotype WSS n = 5 Patient 1 Patient 2
Growth Intrauterine growth restriction 3 - /c
Postnatal growth restriction 5 + a +d
Nervous Developmental Delay 5 + +
Hypotonia n.a. + +
Mild Intellectual disability 5 +b n.a.
Craniofacial Strabismus n.a. + -
Microcephaly 2 - a -d
Wide anterior fontanelle 0 - +
Wide nasal bridge/broad nasal tip 5 + +
Downslanting/small palpebral fissures 5 + +
Hypertelorism ? + +
Right microphthalmia 0 - +
Micrognathia 0 - +
Upper vermillion border thin 3 + n.a.
Skeletal Tapering fingers 3 + +
Broad 1st digit 2 - +
Sacral dimple 4 + +
Rib anomalies (X-ray) 3 n.a. n.a.
2-3 Toe Syndactyly 0 - +
5th finger clinodactyly n.a. + n.a.
Integumentary Hypertrichosis 5 / -
Hypertrichosis cubiti 5 / -
Long/thick eyelashes 5 + +
Thick eyebrows 5 +e +
Thick hair n.a. + +
Legend: + Present; − Absent/questionably present; n.a. not ascertained. a. height (ht.), weight (wt.), head circumference (OFC) <3rd centile; b. IQ 65–75; c. birth
wt. & OFC normal, ht. < 5th centile. d. wt. and ht. (<3rd centile), OFC (<5th centile). e. synophris.
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Data Board consisting of physicians, pathologists, clin-
ical geneticists, laboratory directors, genetic counselors,
and informatics specialists. See Additional file 1 for a de-
tailed description of the bioinformatic methods used for
exome sequencing analysis. Variant Annotator X (VAX)
was used for rich annotation of DNA variants as previ-
ously described [27].
Criteria for high confidence for de novo variants was: qual-
ity score >=Q500 in each individual [28]; variant observed
in <2 reads in any individual parent; variant not observed in
the general population. Clinically significant variants were
confirmed using PCR amplification and Sanger sequencing
of the proband and both parents (Additional file 2).Genomic structure
Due to the high proportion of variants being inherited
from one or the other parent (>99.9%), non-paternity
was excluded in both cases. No homozygous blocks
of >5 Mb were identified in either patient, indicatinga very low probability of significant autozygosity. No
apparent homozygous exon deletions were identified
within the primary gene lists in either patient.Exome sequencing results
Patient 1
A primary gene list of 1,274 genes (Additional file 3) was
generated by searching Human Gene Mutation Database
Professional Version 2012.4 (HGMD), Online Mendelian
Inheritance in Man (OMIM, searched February, 2013),
and GeneTests.org for the following clinically relevant
keywords: developmental delay, (mild) mental retardation,
intellectual disability, hypotonia, (probable) myopathy,
ptosis, dysmorphic features, craniofacial abnormalities,
hypertelorism, bulbous nose, clinodactyly, tapering fingers,
downslanting palpebral fissures, wide nasal bridge,
astigmatism, early tooth eruption, premature adult teeth.
A total of 14,395,023,189 bases of DNA sequence were
generated for Patient 1, resulting in an average read depth
(“coverage”) of 157× across RefSeq coding positions, with
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reads (Additional file 4). A total of 22,275 variants were
identified within exomic loci (21,212 single nucleotide
variants and 1,063 insertion/deletion variants) compared
the human genome reference (hg19/NCBI Build 37).
One de novo variant was identified within the primary
gene list: a heterozygous c.4342T>C (p.Cys1448Arg) mis-
sense variant in the KMT2A/MLL gene (NM_001197104.1).
Alignment view of this variant in the Integrative Genomics
Viewer (IGV) [29] can be seen in Figure 2. In silico predic-
tion was performed using functional prediction algorithms
SIFT (0.00: “Affected Protein Function”) and PolyPhen2
(0.995: “probably damaging”). With over 200× coverage in
the all three members of the trio, this variant is of high
quality and coverage see (Additional file 4).
Other variants of uncertain clinical significance, likely
benign, were identified in VPS13B. Detailed variant
information for the above mentioned variants can be
found in Additional file 5.
Patient 2
A primary gene list of 1,553 genes (Additional file 3).
The following clinical keywords: microphthalmia, poor
growth, growth retardation, micrognathia, hypotonia,
developmental delay, wide fontanelle, dysmorphic, turned-
out hands, syndactyly, pectus excavatum.Figure 2 View of aligned sequence reads spanning the KMT2A varian
Genomics Viewer [39].A total of 10,744,929,539 bases of DNA sequence were
generated for Patient 2, resulting in an average read depth
(“coverage”) of 127× across RefSeq coding positions, with
94% of all targeted positions covered by > =10 inde-
pendent reads (Additional file 4: Materials 3b and 4). A
total of 22,751 variants were identified within exomic
loci (21,498 single nucleotide variants and 1,253 insertion/
deletion variants) compared the human genome reference
(hg19/NCBI Build 37).
One de novo variant was observed within the primary
gene list: a heterozygous c.4086+1G>A variant in the
KMT2A/MLL gene (NM_001197104.1). Alignment view
of this variant in the Integrative Genomics Viewer (IGV)
[29] can be seen in Figure 2. With over 150× coverage in
the all three members of the trio, this variant is of high
quality and coverage (Additional file 4). As this variant
occurs at the first nucleotide of intron 8 of the gene, it is
predicted to result in a loss of function allele due to the
abolition of the canonical splice donor site. However, the
sequence of the mature mRNA produced by this allele
cannot be predicted from sequence alone.
Other heterozygous variants of uncertain clinical signifi-
cance in GFI1B, PCDH15 and MED13 were identified.
Detailed variant information for the above mentioned var-
iants can be found in Additional file 6. No other variants
were identified in patient 2 which were consistent with ants in both patients and their parents using the Integrated
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mode of inheritance. No rare variants in genes associated
with microphthalmia were found.
Conclusions
A subset of WSS is caused by heterozygous de novo variants
in the KMT2A (MLL) gene [9]. This subset is characterized
by mild to moderate developmental delay, dysmorphic facial
features (including: long eyelashes, thick or arched eye-
brows, downslanting palperbral fissures, broad nasal bridge,
and Cupid’s bow abnormality of the upper lip), and hyper-
trichosis cubiti (excessive hair on the elbows). A “slim and
muscular build” was noted in 3/5 initial KMT2A-related
WSS cases. Other features observed in some WSS patients
include high narrow palate, tapering fingers, 5th finger clin-
odactyly and hypotonia. The clinical spectrum of features
associated with WSS is wide and may continue to expand
as additional patients such as these are identified.
Exome sequencing results for these trios are suggestive
of a molecular diagnosis of Wiedemann-Steiner Syndrome
(WSS) in both patients. Our patients shares several of
the features of KMT2A-associated WSS, including postnatal
growth retardation, developmental delay, wide nasal bridge,
broad/bulbous nasal tip, and downslanted palpebral fissures
[9,30]. They do not however have clear hypertrichosis
cubiti, the clinical feature most readily associated - but not
pathognomonic - with WSS. In them the excess of hair is
manifested by thick eyebrows and hair, long thick eyelashes,
and the sacral hypertrichosis observed in patient 2 (Table 1).
In one of our patients and one previously reported individ-
ual with WSS [9], there is history of recurrent infections,
though it remains unclear whether their immune dys-
function is related to KMT2A mutation. Patient 2 has
several clinical features not previously observed in indi-
viduals with WSS, including: unilateral microphthalmia,
micrognathia, 3–4 finger syndactyly, and premature
eruption of adult teeth.
The de novo variant identified in the KMT2A gene in
patient 1 is a missense c.4342T>C variant. To date, all
KMT2A variants reported in WSS patients are prema-
ture truncation variants, suggesting haploinsufficiency as
the disease mechanism. As the c.4342T>C variant does
not result in protein termination, the effect of this variant
on KMT2A protein abundance and/or activity cannot be
confidently predicted. However, this missense variant is
located within a PDH homeodomain zinc finger domain, a
domain thought to coordinate protein-protein interactions
involved in transcriptional activation [31]. The web-based
tool Human Splicing Finder v2.4.1 [32] was unable to pro-
vide a meaningful prediction as to whether this variant
impacts splicing.
Given that typical human exomes carry between zero and
five high confidence de novo coding variants [9,13,14,33-39]
and the inclusive approach to generating the primary genelist (over 1,000 genes included in each case), the identifica-
tion of a previously unreported de novo missense variant in
the KMT2A gene in a single case is not by itself a signifi-
cant finding. However, combined with the phenotypic over-
lap between individuals with de novo variants in KMT2A
with WSS and these two unrelated patients, these find-
ings strongly implicate a causal relationship between the
observed variants and the clinical presentation of these
individuals. Functional analysis or identification of other
patients with the same variants and similar phenotypes
would provide additional support.
This report highlights the value of full trio clinical ex-
ome sequencing for individuals with multiple congenital
anomalies and developmental delay whose features are
not consistent with one particular syndrome, supporting
the model of medical genetics practice recently suggested
by Shashi and colleagues [39]. Without parental sequences,
the variants in KMT2A would not have been singled out
from among many similar heterozygous candidate variants
identified within the primary gene list. Thus full trio exome
sequencing greatly improved the interpretability of the test
in these patients.
Financial considerations are also an important factor
in molecular testing. Full trio clinical exome sequencing
is comparable in cost to gene panel testing [40] and, if
pursued as a second-line test after clinical microarray
analysis (SNP-CMA), is likely a far more efficient use of
resources than iterative single gene testing in cases with
developmental delay and dysmorphic features.Consent
For both patients, a parent or legal guardian consented to
the following statement: “We [the UCLA Clinical Genomics
Center] will use your results to improve Clinical Exome
Sequencing by comparing your data to others”. Additional
written consent was acquired for both patients for the use
of their photographs for research publication.Ethics statement
As the genetic testing data were obtaining using a clinical
test and appropriate written consent for testing was ob-
tained, this report is exempt from ethics approval for med-
ical research of human subjects. All authors have received
training and are compliant with the Health Information
Portability and Accountability Act of 1996 (HIPAA).Additional files
Additional file 1: Bioinformatic Methods used for Data Analysis of
Next Generation Sequencing Results.
Additional file 2: Sanger sequencing traces confirming de novo
variants in the KMT2A gene.
Additional file 3: Primary gene list for patients 1 and 2.
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